Glucose Viaflo Baxter Médico-Farmacêutica

Glucose Viaflo Baxter Médico-Farmacêutica is an intravenous solution for injection that contains glucose as the sole active ingredient. It is supplied in a sterile liquid form without a specified strength, and is marketed in the European Union. The product is classified as an excipient used in parenteral nutrition and fluid replacement, and it requires a prescription (Rx) for use. It is intended for administration by healthcare professionals in clinical settings.

Glucose Viaflo Baxter Médico-Farmacêutica is used when rapid provision of carbohydrate energy is required, particularly in settings where oral intake is not possible or insufficient. It serves as a component of parenteral nutrition regimens and can be employed for immediate correction of low blood glucose levels.

- Management of hypoglycemia in patients unable to take oral glucose. - Supplementation of carbohydrate calories in total parenteral nutrition formulations. - Fluid replacement therapy when combined with electrolytes and vitamins. - Support during perioperative periods to maintain plasma glucose stability. - Treatment of metabolic demands in critically ill or trauma patients.

Intravenous administration of glucose may be associated with a range of physiological responses, most of which are predictable and dose‑related.

Common: - Transient hyperglycemia that resolves with metabolic clearance. - Mild irritation or pain at the injection site. - Electrolyte shifts, particularly decreased serum potassium. - Fluid overload in patients receiving large volumes.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypoglycemia if glucose infusion is abruptly discontinued. - Allergic or anaphylactic reaction to the solution components. - Hyperosmolar hyperglycemic state in susceptible individuals.

Before initiating therapy with Glucose Viaflo Baxter Médico-Farmacêutica, clinicians should evaluate patient-specific factors and monitor relevant clinical parameters to minimize risks.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor serum electrolytes, especially potassium and sodium, during treatment. - Use caution in patients with renal or cardiac insufficiency due to fluid volume concerns. - Avoid rapid infusion in neonates and infants to prevent metabolic disturbances. - Review concomitant insulin therapy to prevent extreme glucose fluctuations. - Ensure sterility; discard any solution that appears cloudy or discolored.

Glucose solutions can interact with other intravenous agents or systemic medications, influencing glucose metabolism or fluid balance.

Avoid: - Concurrent high‑dose insulin infusions without appropriate glucose supplementation. - Co‑administration with other hypertonic dextrose solutions, which may cause excessive osmolar load. - Simultaneous infusion of potassium chloride in concentrations that could precipitate in the line.

Use with caution: - Patients receiving diuretics, as fluid shifts may affect glucose concentration. - Medications that affect renal glucose handling, such as SGLT2 inhibitors. - Catecholamine or glucocorticoid therapy, which can increase endogenous glucose production.